Product Description
ABBV-547 is a next generation anti-IL-23 antibody. ABBV-547 is being investigated as a potential therapy for the treatment of psoriasis. (Sourced from: https://www.abbvie.com/science/pipeline.html)
Mechanisms of Action: IL23 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07232004 |
M26-058 | P1 |
Recruiting |
Healthy Volunteers |
2027-09-01 |
88% |
2025-12-20 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
jRCT2071250150 |
jRCT2071250150 | P1 |
Not yet recruiting |
Unknown |
2028-05-31 |
Recent News Events
Date |
Type |
Title |
|---|